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A B S T R A C T
Objectives: Hepatitis C Virus (HCV) is a significant cause of chronic liver disease. Among at-risk
populations, access to diagnosis and treatment is challenging. We describe an integrated model of care,
Hepcare Europe, developed to address this challenge.
Methods: Using a case-study approach, we describe the cascade of care outcomes at all sites. Cost analyses
estimated the cost per person screened and linked to care.
Results: A total of 2608 participants were recruited across 218 clinical sites. HCV antibody test results
were obtained for 2568(985%); 1074(418%) were antibody-positive, 687(605%) tested positive for
HCV-RNA, 650(605%) were linked to care, and 319(435%) started treatment. 196(614%) of treatment
initiates achieved a Sustained Viral Response (SVR) at dataset closure,108(339%) were still on treatment,
eight (27%) defaulted from treatment, and seven (26%) had virologic failure or died. The cost per person
screened varied from s194 to s635, while the cost per person linked to care varied from s364 to s2035.
Conclusions: Hepcare enhanced access to HCV treatment and cure, and costs were affordable in all
settings, offering a framework for scale-up and reproducibility.
© 2020 Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Background
The number of people with chronic Hepatitis C Virus (HCV)
infection in the European Union/European Economic Area (EU/
EEA) region is estimated to be 5.6 million (European Centre for
Disease Prevention and C, 2016). Chronic HCV infection can remain
asymptomatic, leaving people unaware of their status. In the EU,
633% of all HCV infections are undiagnosed, with considerable
variation between countries (Razavi et al., 2017). The HCV care
cascade has numerous stages, from screening to cure. Historically,
attrition from each stage of the cascade was high, with 59% of
those testing HCV antibody-positive achieving cure pre-DAA
availability (Simmons et al., 2018). In Ireland, our pilot study
among the homeless, designed based on a systematic review
(Lazarus et al., 2014), showed that out of 597 patients, 199 were
antibody positive, and only two completed HCV treatment,
demonstrating the need for alternative models of care (Lambert
et al., 2019). Recently (Anon, 2020a), WHO (World Health
Organization) stated that better HCV models of care are needed
to retain patients along the care cascade. An efficient health system
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G. Avramovic, M. Reilly, W. Cullen et al. International Journal of Infectious Diseases 101 (2020) 374–379he HepCare Europe project sought to improve care systems for
ulnerable HCV infected populations, assisting progress towards
CV elimination in line with WHO recommendations (Swan et al.,
018) and the EU HCV Manifesto (Anon, 2020b). In light of new
echnological and medical breakthroughs, we endeavored to
mprove outcomes at each stage of the care cascade by
mplementing interventions at four sites, London, Bucharest,
eville, Dublin (Swan et al., 2018), performing economic analyses
o determine whether interventions were a value for the money.
ethods
tudy design
A service innovation project and a mixed-methods, pre-post
ntervention study, Hepcare has
designed and delivered interventions in Dublin, London, Seville,
nd Bucharest to enhance People Who Inject Drugs (PWID)
ngagement and retention in the HCV care cascade. The study
tarted in May 2016 and ended in August 2019 at all sites. We are
resenting a case study of this integrated system of care for
ulnerable populations (Swan et al., 2018). A description of the
odel of care is shown in Fig. 1. The same model was applied at
ach site. Each hospital targeted community organizations in their
atchment area for outreach. Community organizations, therefore,
aried from city to city. PWID were targeted for intensified HCV
creenings (HEPCHECK) (Swan et al., 2018; Cha et al., 2013), linked
o care (HEPLINK)(McCombe et al., 2018) and supported to remain
ngaged with the cascade of care using peer support (HEPFRIEND)
McCombe et al., 2019). HEPED developed and delivered educa-
ional interventions to prepare affected communities for HCV
esting, assessment, and treatment and prepare healthcare
roviders to act as partners in a shared care primary/secondary
artnership to treat HCV (McCombe et al., 2019). HEPCOST
valuated the cost of the various Hepcare interventions in different
ettings.
Quantitative data on the cascade of care and costs of the
ifferent initiatives were collected. In Dublin, London, and
ucharest, healthcare providers collected intervention costs; costs
ere not available from the Seville intervention due to staffing
imitations (Anon, 2020c). Cost analyses were undertaken using
op-down and ingredients-based approaches, depending on the
nformation available at each site. The most up-to-date costs for all
esources used were collected, and all retrospective costs were
nflated to 2018 Euros using the Consumer Price Index for health.
ountry-specific prices were converted to a standard price index
y adjusting for GDP differences using the purchasing power parity
alue for 2018 (Anon, 2020d). Financial and economic costs were
collected and classified as capital (one-off costs) or recurrent (staff
and test costs). Data collected for project activities included
intervention set-up, non-research intervention activities, and staff
usage. Expenditure costs were recorded. Research-related costs
were excluded. Costs for capital items were annualized over five
years with computer equipment costs annualized over two years.
The outcomes of cost per patient screened, diagnosed with an
infection, or linked to care was estimated by dividing the total cost
by the number of individuals in each category. The cost per person
treated was not estimated because treatment rates were affected
by differences in regulatory barriers across settings, restricting
some patients from obtaining treatment.
Settings and recruitment
The study was conducted across four European cities: Dublin,
Cork(Ireland), London(UK), Seville(Spain), and Bucharest(Romania),
and targeted high-risk populations. Recruitment was carried out by
each city hospital in its surrounding community settings through
outreach in community addiction, prison, homeless services, and GP
practices prescribing methadone (Anon, 2020e).
Results
Networks created
The types and numbers of services that participated in the
Hepcare outreach initiative varied from city to city. Table 1
presents types of clinical services that participated in the project,
with outreach being undertaken across 218 services in four
European cities, including homeless services, addiction services,
and prisons. More community sites were reached in London due to
the use of a mobile health unit. Seville mostly targeted drug
treatment centers and NGOs, whereas Dublin mainly targeted
prison and GP practices. Bucharest targeted night shelters and
community organizations. Across the European sites, homeless
services represent 491%, and drug addiction centers represent
349% of the services reached.
Type of testing
The rapid oral swab test was the most popular antibody testing
method (501%, n = 1291). In Ireland, phlebotomy was used as a
first testing option among prisoners due to an ethical ruling.
Cascade of care
The cascade of care results and their breakdown by site are
shown in Table 2. Overall, 2608 participants were recruited across
the four European countries, with 2568(985%) participants
receiving an HCV antibody test. Of these, 1074(418%) had an
HCV antibody positive result, and 687 (605%) were HCV-RNA
positive. Overall, 650(640%) were then linked to care, and 319
(435%) started treatment. At dataset closure (Jul 31, 2019), 196
(614%) of the participants that started treatment had achieved
SVR, 108(339%) were still on treatment, and twelve (4%) had other
treatment outcomes. The rates of HCV antibody-positive partic-
ipants linked to care in each country varied depending on the
system used. For some sites, RNA testing was offered in the
community, whereas other sites could only undertake RNA testingFig. 1. The HepCare European System.
37after linkage to care in hospitals. Ireland had the highest
proportion of participants linked to care that subsequently started
treatment n = 104 (64.2%). The effectiveness of HCV DAA treatment
is verified in our study with 196(965%) individuals achieving SVR
of the 203 that completed treatment; Romania had a higher
percentage of virological failures (10%).5
G. Avramovic, M. Reilly, W. Cullen et al. International Journal of Infectious Diseases 101 (2020) 374–379Economic analysis
Table 3 presents the total costs of the main HepCare
interventions in Dublin, Bucharest, and London. These costs do
not include the costs of treatment or treatment workup. The
London outreach intervention was most expensive (£97,472 or
s112,093), with active case finding in a mobile van. Next was the
prison mass-screening intervention in Dublin (s81,505), the
intervention in OST GP practices in Dublin (s64,806), and multiple
interventions in Bucharest (s56,647). Dublin's main cost compo-
nents were overheads, primarily due to the inclusion of manage-
ment staff time during implementation.
In contrast, salary costs for undertaking screening were the
most expensive component in London (58% of total costs), while in
Bucharest, the highest costs were for training (23%) and peer
support (23%). The high London salary cost for screening is related
to having an HCV specialist nurse, peer, and driver for the mobile
intervention van. In contrast, salary costs for screening in
Bucharest were less costly (7%) than in other settings.
Table 4 compares the costs per outcome for each setting. These
outcomes differ from what is presented in Table 2 because the cost
analysis only evaluated two Dublin interventions and one in
London. Additionally, the London intervention was priced over one
financial year (2017/18), and so patient outcomes were taken from
that period. The cost per person screened varies 3-times across
settings after adjustment to 2018 Irish Euros, with the two Dublin
interventions having the lowest (prison screening s194) and
highest (OST screening s635) unit cost. The high cost of screening
in the OST clinic in Dublin is due to the small number of patients
Table 1
Types of clinical service that were outreached to by site.
Bucharest Romania Dublin/Cork Ireland Seville Spain London UK Total
Homeless Services 0 (0%) 2 (1%) 0 (0%) 105 (48%) 107 (49%)
Drug Addiction Centre 3 (1%) 1 (05%) 8 (4%) 64 (29%) 76 (35%)
General Practice (HepLink site) 0 (0%) 14 (6%) 3 (1%) 2 (1%) 19 (9%)
Prison 2 (1%) 1 (05%) 0 (0%) 0 (0%) 3 (1%)
Night Shelter 3 (1%) 0 (0%) 0 (0%) 0 (0%) 3 (1%)
Needle Exchanges 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)
NGO 2 (1%) 0 (0%) 5 (2%) 0 (0%) 7 (3%)
Other (healthcare facilities, home visits, EDa LTFU case finding project (VIRAEMIC)) 1 (0.5%) 0 (0%) 0 (0%) 2 (1%) 3 (1%)
Total (% of all orgs.) 11 (5%) 18 (8%) 16 (7%) 173 (79%) 218 (100%)
a ED emergency department.
Table 2
Cascade of Care Results by country.
Romania Ireland Spain England Total
Individuals recruited 525 812 636 635 2608
Participants antibody test results recorded 525 (100%) 772 (959%) 636 (100%) 635 (100%) 2568 (98.5%)
HCV Ab positive results 230 (438%) 257 (330 %) 197 (310 %) 390 (614%) 1074 (418%)
RNA positive HCV infectionsa 71 (309%) 162 (630%) 108 (548%) 346 (887%) 687 (605%)
Participants linked to carea 151 (656%) 176 (685%) 104 (528%) 219 (561%) 650 (64%)
Participants put on Treatment 24 (338%) 104 (642%) 76 (704%) 115 (332%) 319 (435%)
Still on treatment results pending 4 (167%) 44 (423%) 20 (263%) 40 (348%) 108 (339%)
Completed treatment (including virologic failure and death) 20 (833%) 58 (557%) 54 (710%) 71 (617%) 203 (679%)
Abandon treatment 0 (0%) 2 (2%) 2 (26%) 4 (35%) 8 (27%)
Achieved SVR vs put on treatment 18 (75%) 57 (548%) 52 (684%) 69 (60%) 196 (614%)
Achieved SVR vs completed treatment 18 (90%) 57 (983%) 52 (963%) 69 (972%) 196 (965%)
Virologic failures vs completed treatment 2 (10%) 1 (17%) 2 (37%) 0 (0%) 5 (25%)
Death during treatment 0 0 0 2 (28%) 2 (01%)
a depending on the setting it was not always possibile to test for those RNA positive at community sites. Some sites could only accommodate oral POCT in which case
patients were first linked to care and then phlebotomy was performed for the RNA testing. Other sites had the capacity to do phlebotomy on those who were antibody positive
and the linkage to care was done later. So the percentages were calculated in relation to those who tested antibody positive. the OST prescribing GP practices in Ireland had to
refer all Antibody positive patients to the hospital for RNA testing. Romania had to send all Antibody positive patients to the hospital for RNA testing.
Table 3
Total costs (in 2018 euro or pounds) across settings and allocated by cost category (overheads/equipment, test cost, fibroscan, training, staff screening and peer support).
Cost Category Bucharest (varied interventionsb) Dublin (OST) Dublin (prison) Londonc(Outreach)
Total Cost % Total Cost % Total Cost % Total Cost %
Overheads/ Equipment s7905 14 s38,564 60 s33,400 41 a a
Test cost (Ab/RNA) s9977 18 s4064 6 s9802 12 £5047 5
Fibroscan s8827 16 s2045 3 s799 1 £15,142 15
Training s12,704 23 s6823 11 s2374 3 0 0
Salary costs for screening s4615 7 s12,134 19 s25,206 31 £56,086 58
Peer support s12,619 22 s1176 2 s9924 12 £21,197 22
Total Cost s56,647 s64,806 s81,505 £97,472
a Overheads in London were not separated out, instead overheads were shared across the care cascade.
b Includes interventions in homeless shelters, addiction services, prisons, through NGO and in infectious disease wards. The test cost category (Ab/RNA) denotes Ab
screening for London and Bucharest, whereas Dublin(OST) and Dublin (Prison) tested for RNA.
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inked to care, reflecting that only a proportion of people tested are
nfected, which varies by setting, and not all those infected are
inked to care. Although the prison intervention in Dublin has the
owest unit cost for screening, it has the highest unit cost per
erson diagnosed due to the low proportion of HCV infected
atients (12% were RNA+). The cost per person linked to care for the
ondon outreach intervention is higher than the cost per person
iagnosed, due to the cost of using peer support to facilitate patient
ttendance in secondary care.
iscussion
HepCare accessed a high number of vulnerable patients in all
our cities through joining up and improving services. Although it
as thought that oral swabs were the best testing method for the
roject, in practice, a key part of the system’s success relied on
exibility in the testing methods to engage community partners.
Despite significant successes, the HepCare system’s effective-
ess was limited because of social, regulatory, and medical reasons,
s well as the capacity to access certain populations. Bucharest
aced medical and regulatory barriers, which meant they could
nly treat 24(338%) of their 71 diagnosed HCV RNA + participants.
ntil 2018, DAA treatment was only available for advanced liver
brosis (Metavir F3 and F4 score) in Romania, so most patients
rom Bucharest with lower fibrosis stages were not eligible for
eimbursed investigations and treatment by the national insurance
ystem. Also, some patients may not have been treated with
uitable DAA regimens because genotype testing was unavailable
or PWID in Bucharest, contributing to the two reported virologic
ailures (10% of HepCare Bucharest). Most importantly, the
omanian National Insurance scheme requires an individual to
ave an identity card, a health-card, and insurance before
ccessing HCV diagnostics and treatment. This presented a
ignificant barrier because 143 HCV antibody-positive prisoners
ere neither tested for HCV-RNA nor treated because they did not
ulfill these criteria. In Dublin, the limited healthcare budget and
igh cost of DAA regimens restricted availability of treatment, from
uly 2017 to February 2018 with a freeze of new treatments
mposed by the government. This significantly disrupted the
epCare ‘cascade of care’ among targeted vulnerable populations
here timeliness is key to keeping patients engaged in care.
wide variations between settings due to differences in HCV
prevalence, availability of confirmatory testing, and barriers to
linkage to care.
Hepatitis C care has undergone tremendous changes due to
technological advances, including non-invasive rapid tests (e.g.,
Oraquick1 and Fibroscan technology)(Anon, 2020f; Pallarés et al.,
2018; Sebastiani et al., 2014) and DAA treatments (Schlabe and
Rockstroh, 2018). This has enabled new possibilities and the rapid
expansion of systems of care for HCV. The Hepatitis C Assessment
and Testing (HepCAT) project in New York, a prospective cross-
sectional project conducted in three primary care clinics in low
economic activity areas (Drainoni et al., 2012), increased both
numbers screened and diagnosed. It increased HCV diagnosis and
linkage to care but did not report subjects achieving SVR.
Conversely, HepCATT (Hepatitis C Awareness Through to Treat-
ment), UK, had two branches recruiting from primary care and
drug treatment services (Roberts et al., 2016; Harrison et al., 2019).
The HepCATT drug treatment service study was a nurse-led
intervention to increase case-finding and linkage to care, utilizing
‘buddies’ and peers. Compared with baseline and control districts,
there was strong evidence that HCV testing and engagement with
HCV therapy increased substantially. An economic evaluation of
the intervention showed comparable costs for screening and
engagement as found for HepCare, with costs per person screened
(reflex testing of dried blood spots) ranging from £106-£207
(management costs not included) (Anon, 2020g). Other work in
Tayside (Scotland) (Dillon, 2018) has created a new pathway that
allows a pharmacist to undertake HCV testing, prescribe medicine,
and observe patients taking medication (Andrew et al., 2020). This
Scottish model was also applied in Opioid Substitution Therapy
(OST) clinics and Needle and Syringe Exchange Programmes (NSP).
This model is at the forefront of new systems of care that devolve
HCV care to the community. It is not yet easily adaptable to other
settings because pharmacists have no legal authority to undertake
such services. Compared to results before HepCare (McCombe
et al., 2018; Anon, 2020e), the system improved outcomes. Costs of
the HepCare interventions compare favorably with the range of
costs per case detected (£2453107) from a systematic review of
economic evaluations of screening for HCV (Anon, 2020h) and the
costs from more recent intervention evaluations (£100 to £318 per
person screened) (Schackman et al., 2018; Ward et al., 2020; Radley
et al., 2017).
able 4
omparison of costs (in euros) per patient screened, diagnosed or linked to care by intervention setting.











PPS adjusted unit cost
Dublin(OST)(s) 102 s635 s635 57 s1137 s1137 43 s1507 s1507
London (£) 273 £248* spps513 121 £558* spps1154 110 £1171* spps2421
Dublin(Prison) (s) 419 s194 s194 50 s1628 s1628 40 s2035 s2035
Bucharest(s) 525 s107 spps313 230 s244 spps713 154 s364 spps1064
Bucharest (Shelter) 163 s73 s213 9 s1326 s3874 4 s2983 s8716
Bucharest(OST) 70 s151 s441 59 s180 s526 25 s424 s1239
Bucharest(Prison) 153 s106 s310 57 s285 s833 43 s378 s1104
Bucharest (NGO) 56 s94 s274 30 s176 s514 17 s311 s909
Bucharest(ID
Wards)
83 s152 s444 75 s168 s491 65 s194 s567
ctual country specific costs are included, as well as adjusted costs transformed to the Irish euro GDP value of 2018. GBP converted to EUR at 1.15 EUR/GBP. Costs for Bucharest
nd London then adjusted to Irish Euros using purchasing power standard ratios, with 1.87 for Ireland, 1.04 for London, and 0.64 for Bucharest.epcare Seville could not access two key populations, prisoners
nd immigrants. In London, some key populations such as the
oma traveler communities, and sex workers, were hard to reach
ith existing peers. Finally, our cost analysis implicates the
ffordability of the interventions, although a comparison of the
osts per outcome reached at each point in the care cascade reveals37Devolution of HCV care to the community effectively reaches
vulnerable populations, but cannot supply the specialty care
needed for complex cases including cirrhotics. HepCare is the
blueprint model that can be used across a range of healthcare
systems and community settings for micro-elimination of HCV.
Focusing on one disease may be a weakness, although those7
G. Avramovic, M. Reilly, W. Cullen et al. International Journal of Infectious Diseases 101 (2020) 374–379engaged in HepCare may be more likely to access other health
services in the future. Projects such as INTEGRATE (Anon, 2020i)
are focussing on integrating various diseases.
Strengths of cost analysis include collecting empirical cost
data from numerous interventions in three countries, aiding
generalisability of findings to other European settings. However,
limitations include being unable to undertake a cost analysis in
Spain, which used a nurse-led model similar to London, but
without a mobile unit. The costing methods used in different
countries were also slightly different to make the best use of
available information. While this means the results may be less
comparable, it reflects the nature of the populations being
screened and the different approaches needed in each. The
variation in costs across settings is due to differences in the
interventions undertaken and local differences affecting the
investment needed in staff time versus materials. The cost
analyses did not include the cost of treatment or related visits and
diagnostics because the focus was on the costs of screening and
linkage to care; also, treatment rates were affected by local
regulatory restrictions. At the time, all treatments (except in the
Dublin prison) were done in hospitals, meaning that the
treatment costs should be similar in each setting regardless of
the screening and linkage to care intervention. This will change as
treatment moves to the community. We also did not undertake a
full cost-effectiveness analysis because this is the focus of
separate analyses – here we compared the differences in unit
costs of the interventions across settings, which is useful
information for other settings planning the resource needs for
undertaking similar interventions. Finally, these were pilot
interventions in which we were unable to assess the resources
needed to scale them up to the broader population. As
interventions scale-up, there will be cost savings from reduced
managerial or training costs. Also, over time, prevalence is likely
to change, with high rates of treatment leading to a reduced
prevalence, and therefore the cost per diagnosis may increase
unless screening becomes more targeted. In high incidence
populations such as PWID, this change is likely to be slower due to
re-infections.
HepCare has impacted on policy and practice. In Dublin, the
project developed an advocacy document (HEPMAP) disseminated
to the Irish Health Service Executive. In Bucharest, recommenda-
tions were sent to the National Infectious Diseases Committee and
Director of the National Programmes in the Ministry of Health.
HepCare successfully changed HCV treatment policies toward at-
risk populations by promoting the recent removal of disease-based
and laboratory restrictions, permitting the treatment of all patients
(September 2018). In Seville, the HepCare model was replicated at
other tertiary care centers in eight Andalusian provinces. Outside
Andalusia, centers in Valencia and Galicia are planning to
implement the model. In London, the HepCare mobile outreach
model of care has inspired other services, including the Hepatitis C
Trust, which is launching a similar mobile screening service with
the NHS in southern England to directly access hard-to-reach
patients based on the HepCare model. St Mungo’s, the largest
provider of homeless accommodation in London, now has regular
screening programs due to the partnership.
The cost analysis has revealed that numerous different
interventions can be affordable across Europe. One important
lesson is that the yield of testing is a significant indicator of costs,
varying unexpectedly across testing settings. In Bucharest, high
existing services will be more efficient than setting up entirely new
interventions.
Conclusion
This first multi-city study offers a framework for scale-up and
reproducibility for achieving HCV elimination goals. However,
vulnerable populations have numerous health conditions,
highlighting the importance of integrating multiple health needs
as initiatives are expanded. To achieve HCV elimination and other
targets of the Sustainable Development Goals (SDG) 2030 agenda,
it is imperative to reach vulnerable populations not accessing care
and leave no one behind.
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